Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States...
Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy
Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of...
Zai Lab Partners with MediLink Therapeutics to Develop YL212 DLL3 ADC
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688), a China-based biopharmaceutical company, has announced a strategic...
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the...
OBiO Technology and ImmVira Partner on Oncolytic Virus Project for BLA Filing and Commercialization
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading gene therapy specialist based in China,...
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou,...
CSPC Pharmaceutical Group Reports 11% YOY Revenue Growth in 2022 Financial Results
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its 2022 financial report, recording RMB...
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease...
GSK Reports Q1 2023 Revenue Dip Amid COVID-19 Treatment Decline, Underlying Growth
UK-based multinational GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial results for the first...
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III...
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center,...
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical...
MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial...
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market...
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ,...
NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings
The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts...
Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma
Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd...
LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product
Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with...
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...